Chinese Firm Wins U.S. National Security Approval with Lobbying Help from Trump Jr.'s Associate
Chinese business hired lobbying firm with ties to Don Jr, then scored a win in Washington
The Economic Times
Image: The Economic Times
A lobbying firm connected to Donald Trump Jr. facilitated a meeting that helped the Chinese company Grand Pharmaceutical Group secure a favorable decision from the Committee on Foreign Investment in the U.S. (CFIUS). This decision allowed Grand Pharma to maintain its investment in a U.S. startup, despite concerns over national security implications.
- 01Grand Pharmaceutical Group successfully lobbied CFIUS with help from Checkmate, a firm linked to Donald Trump Jr.
- 02CFIUS rejected a U.S. startup's request for a national security review of Grand Pharma's investment.
- 03The case raised concerns about foreign influence on U.S. national security decisions.
- 04FastWave, the U.S. startup, is facing financial distress and claims procedural irregularities in the CFIUS process.
- 05Democratic Senator Elizabeth Warren and other experts have criticized the influence of Trump-connected lobbyists on national security matters.
Advertisement
In-Article Ad
A lobbying firm named Checkmate, led by Ches McDowell, a friend of Donald Trump Jr., assisted China's Grand Pharmaceutical Group in a case involving a U.S. startup, FastWave. FastWave sought to remove Grand Pharma as an investor due to concerns over potential national security risks, but CFIUS ultimately sided with Grand Pharma, rejecting FastWave's request for a review. This decision, which has not been previously reported, indicates a significant win for a Chinese firm in the U.S. regulatory landscape. Critics, including Democratic Senator Elizabeth Warren, have expressed concern that such lobbying efforts could undermine U.S. national security interests. FastWave claims it is facing bankruptcy and has accused CFIUS of procedural irregularities, stating that it was not given a fair chance to address concerns raised during the review process. The case highlights the complexities of foreign investment in sensitive sectors and the potential influence of lobbyists in shaping national security decisions.
Advertisement
In-Article Ad
The decision allows Grand Pharma to retain its investment in FastWave, which is crucial for the startup's financial stability and future operations. This outcome raises concerns about the implications for U.S. national security and the integrity of regulatory processes.
Advertisement
In-Article Ad
Reader Poll
Do you believe foreign companies should be allowed to lobby U.S. government agencies?
Connecting to poll...
More about Checkmate
Read the original article
Visit the source for the complete story.